BD: Medical Supplies, Devices and Technology; Laboratory Products; Antibodies

BD (Becton, Dickinson and Company) is a global medical technology company that is focused on improving drug delivery, enhancing the diagnosis of infectious diseases and cancers, and advancing drug discovery. BD develops, manufactures and sells medical supplies, devices, laboratory instruments, antibodies, reagents and diagnostic products through its three segments: BD Medical, BD Diagnostics and BD Biosciences. It serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Learn more about BD »

BD has entered what may be its most productive period so far for developing new and innovative products having the potential to impact major healthcare challenges around the world.

	Cancer Diagnostics		Diabetes Education
	Enhancing Pharmaceutical Therapies		Global Health
	Social Responsibility		Reducing the Spread of Infection

	BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections »
	BD to Present at Investor Healthcare Conferences »
	BD Receives FDA Approval for the BD FocalPoint™ GS Imaging System to Enhance the Detection of Cervical Cancer »
	BD Launches 8mm BD AutoShield™ Pen Needle »
	BD Board Declares Dividend Increase and Authorizes Additional Share Repurchases »
	BD Announces Health Canada Licensing of Novel Molecular Assay for Detection of Clostridium difficile Toxin B Gene »
	BD Launches BD Atomic Edge™ Safety LRI Knives »
	BD Announces Results for Fourth Fiscal Quarter and Full Year »
	BD Announces Executive Appointments of President and Chief Financial Officer »
	BD to Present at Investor Healthcare Conferences »
	Collaborative Partnership Formed to Improve the Health of Health Care Workers »
	United Nations Secretary-General Statement Regarding HIV/AIDS (PDF) »
	BD Sponsors Campaign to Raise Awareness of XDR-TB (Extensively Drug-Resistant Tuberculosis) »
	BD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call »
	BD Biosciences to Open New Animal-Free, Antibiotic-Free Cell Culture Media Manufacturing Facility »
	BD Breaks Ground on Major Manufacturing Facility in Tatabánya »
	Luminex and BD Sign Agreement to Create Diagnostic Tests for Cancer »
	BD Board Declares Dividend »
	BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections »
	BD Celebrates Opening of New Manufacturing Center in Québec »
	New BD BACTEC™ FX Blood Culture Instrument with the BD EpiCenter™ Operating System can Facilitate Fast and Effective Clinical Decisions for Patients with Bacterial Infections »
	BD Announces Acquisition of Cytopeia »
	BD Announces CE Marking of the BD GeneOhm™ VanR Molecular Test for the Rapid Detection of Vancomycin Resistance »
	BD and Direct Relief International Launch Second Volunteer Service Trip to Improve Healthcare in Ghana »
	BD Venflon™ Pro Safety Catheter Wins Award in Prestigious International Design Competition »
	First European Application Filed for Product Using Innovative Intradermal Microinjection System BD Soluvia™ »

Site Map Privacy \| Terms & Conditions \| Permission Request \| Trademarks BD Worldwide
BD 1 Becton Drive Franklin Lakes, NJ USA 07417 201.847.6800
Unless otherwise noted, BD, BD Logo and all other trademarks are property of Becton, Dickinson and Company. © 2009 BD